Name: Pearce IP
Address: Level 5/20 Bond St, Sydney, NSW, 2000, AU
Telephone: (02) 9023 9988
Price range: $$

Read our latest updates & insights

Stay informed about important legal and industry news with our blogs and weekly BioBlast® updates.

Pearce IP BioBlast® w/e 26 November 2021

By Naomi Pearce | Nov 29, 2021

Read more

21 Nov 21 | CN | Innovent released the results of a Ph III study of sintilimab and BYVASDA® (bevacizumab biosimilar) combined with chemotherapy in patients with EGFR-mutated non-squ...
Breaking News – Parliament delivers early Christmas present for Health Care

By Naomi Pearce | Nov 26, 2021

Read more

In the last sitting of Parliament for 2021, the House of Representatives delivered the long-awaited Zimmerman Report, more formally entitled “The new frontier—delivering better heal...
Naomi Pearce is Lawyers Weekly WIL Partner of the Year 2021

By Pearce IP | Nov 26, 2021

Read more

Pearce IP is proud to announce that Founding Principal and Executive Lawyer, Patent & Trade Mark Attorney, Naomi Pearce, was awarded the title of 2021 Partner of the Year (SME l...
Mochida and Ayumi launch 100mg/mL adalimumab biosimilar in Japan

By Bioblast Editor | Nov 25, 2021

Read more

Mochida Pharmaceutical and Ayumi Pharmaceutical announced the launch of high-dose 100mg/mL Adalimumab BS MA (adalimumab biosimilar) in Japan.
Disclaimer amendment allowed in mastitis patent

By Naomi Pearce | Nov 25, 2021

Read more

Date: 25 November 2021Court: Federal Court of AustraliaJudge: Besanko J
Background
This appeal from a decision of the Australian Patent Office concerned the allowabilit...
New study of belimumab after rituximab in SLE demonstrates promising results

By Bioblast Editor | Nov 24, 2021

Read more

A new study of belimumab after rituximab reported a reduction of serum IgG anti-double-stranded DNA antibody levels and the risk for severe flare in systemic lupus erythematosus refractory in comparison to conventional therapy.
Pearce IP BioBlast®: w/e 19 November 2021

By Naomi Pearce | Nov 22, 2021

Read more

15 Nov 21 | EU | Celltrion announced that the EC has approved Regkirona® (regdanvimab, CT-P59) for adults with COVID-19 who do not require supplemental oxygen and who are at increas...
Dong-A ST completes patient enrolment for Ph III trials of DMB-3115 (proposed denosumab biosimilar)

By Bioblast Editor | Nov 22, 2021

Read more

Korea Biomedical Review reported that Dong-A ST has completed patient enrolment for Ph III trials of DMB-3115 (proposed denosumab biosimilar) in patients with moderate to severe chronic plaque psoriasis.
Innovent releases the results of Ph III studies of sintilimab and BYVASDA® (bevacizumab biosimilar) combined with chemotherapy in lung cancer

By Bioblast Editor | Nov 21, 2021

Read more

Innovent released the results of a Ph III study of sintilimab and BYVASDA® (bevacizumab biosimilar) combined with chemotherapy in patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed after EGFT-TKI therapy.
MSD completes cash tender offer for all of the outstanding shares of common stock of Acceleron Pharma

By Bioblast Editor | Nov 19, 2021

Read more

MSD announced that it has successfully completed the cash tender offer for all of the outstanding shares of common stock of Acceleron Pharma through its subsidiary Astros Merger Sub, Inc. MSD announced that it intends to complete the acquisition through a merger of Astros ...